Literature DB >> 30668209

Invasive pneumococcal disease in relation to vaccine type serotypes.

Paeton L Wantuch1, Fikri Y Avci1.   

Abstract

Since 1983 the world has been introduced to four vaccines combating disease caused by Streptococcus pneumoniae bacteria. However, despite vaccination programs disease caused by S. pneumoniae continues to lead to high morbidity and mortality worldwide. Surprisingly, instances of invasive pneumococcal disease (IPD) are still highly attributed to serotypes found in the current vaccine, such as serotypes 3 and 19A. Conversely, non-conjugate vaccine serotypes, such as 35B, are increasing and of rising interest. The persistence of vaccine type serotypes and the increase in non-conjugate vaccine type serotypes show the need for further research into conjugate vaccine design and the need for novel strategies to combat IPD. Abbreviation: IPD: invasive pneumococcal disease.

Entities:  

Keywords:  capsular polysaccharide; conjugate vaccines; pneumonia; serotype 19A; serotype 3

Year:  2019        PMID: 30668209      PMCID: PMC6605867          DOI: 10.1080/21645515.2018.1564444

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  16 in total

1.  Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

Authors:  Marc J M Bonten; Susanne M Huijts; Marieke Bolkenbaas; Chris Webber; Scott Patterson; Samantha Gault; Cornelis H van Werkhoven; Anna M M van Deursen; Elisabeth A M Sanders; Theo J M Verheij; Michael Patton; Anne McDonough; Anita Moradoghli-Haftvani; Helen Smith; Tracey Mellelieu; Michael W Pride; Graham Crowther; Beate Schmoele-Thoma; Daniel A Scott; Kathrin U Jansen; Rita Lobatto; Bas Oosterman; Nils Visser; Esther Caspers; Andre Smorenburg; Emilio A Emini; William C Gruber; Diederick E Grobbee
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

Review 2.  Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis.

Authors:  Daniel M Weinberger; Zitta B Harboe; Elisabeth A M Sanders; Moses Ndiritu; Keith P Klugman; Simon Rückinger; Ron Dagan; Richard Adegbola; Felicity Cutts; Hope L Johnson; Katherine L O'Brien; J Anthony Scott; Marc Lipsitch
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

Review 3.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Identification and characterization of the Streptococcus pneumoniae type 3 capsule-specific glycoside hydrolase of Paenibacillus species 32352.

Authors:  Dustin R Middleton; Xing Zhang; Paeton L Wantuch; Ahmet Ozdilek; Xinyue Liu; Rachel LoPilato; Nikhil Gangasani; Robert Bridger; Lance Wells; Robert J Linhardt; Fikri Y Avci
Journal:  Glycobiology       Date:  2018-02-01       Impact factor: 4.313

5.  A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design.

Authors:  Fikri Y Avci; Xiangming Li; Moriya Tsuji; Dennis L Kasper
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

Review 6.  Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review.

Authors:  Naomi Sugimoto; Yuka Yamagishi; Jun Hirai; Daisuke Sakanashi; Hiroyuki Suematsu; Naoya Nishiyama; Yusuke Koizumi; Hiroshige Mikamo
Journal:  BMC Res Notes       Date:  2017-01-04

7.  Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.

Authors:  Catarina Silva-Costa; Maria João Brito; Marcos D Pinho; Ana Friães; Sandra I Aguiar; M Ramirez; Jose Melo-Cristino
Journal:  Emerg Infect Dis       Date:  2018-07       Impact factor: 6.883

8.  Enzymatic Hydrolysis of Pneumococcal Capsular Polysaccharide Renders the Bacterium Vulnerable to Host Defense.

Authors:  Dustin R Middleton; Amy V Paschall; Jeremy A Duke; Fikri Y Avci
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

9.  T Cell-Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide of Streptococcus pneumoniae.

Authors:  Dustin R Middleton; Lina Sun; Amy V Paschall; Fikri Y Avci
Journal:  J Immunol       Date:  2017-05-31       Impact factor: 5.422

10.  Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited.

Authors:  Pernille Martens; Signe Westring Worm; Bettina Lundgren; Helle Bossen Konradsen; Thomas Benfield
Journal:  BMC Infect Dis       Date:  2004-06-30       Impact factor: 3.090

View more
  10 in total

1.  Isolation and characterization of new human carrier peptides from two important vaccine immunogens.

Authors:  Paeton L Wantuch; Lina Sun; Rachel K LoPilato; Jarrod J Mousa; Robert S Haltiwanger; Fikri Y Avci
Journal:  Vaccine       Date:  2020-01-28       Impact factor: 3.641

Review 2.  Pneumococcal Surface Proteins as Virulence Factors, Immunogens, and Conserved Vaccine Targets.

Authors:  Javid Aceil; Fikri Y Avci
Journal:  Front Cell Infect Microbiol       Date:  2022-05-12       Impact factor: 6.073

3.  A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States.

Authors:  David Fitz-Patrick; Mariano Young; Daniel A Scott; Ingrid L Scully; Gary Baugher; Yahong Peng; Kathrin U Jansen; William Gruber; Wendy Watson
Journal:  Hum Vaccin Immunother       Date:  2021-02-05       Impact factor: 3.452

4.  Broadly Reactive Human Monoclonal Antibodies Targeting the Pneumococcal Histidine Triad Protein Protect against Fatal Pneumococcal Infection.

Authors:  Jiachen Huang; Aaron D Gingerich; Fredejah Royer; Amy V Paschall; Alma Pena-Briseno; Fikri Y Avci; Jarrod J Mousa
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

5.  Shionone-Targeted Pneumolysin to Ameliorate Acute Lung Injury Induced by Streptococcus pneumoniae In Vivo and In Vitro.

Authors:  Runbao Du; Tian Wang; Hongfa Lv; Yinuo Zou; Xiaoning Hou; Nana Hou; Peng Zhang; Hongen Li; Gefu Chi
Journal:  Molecules       Date:  2022-09-23       Impact factor: 4.927

6.  Characterization of the β-glucuronidase Pn3Pase as the founding member of glycoside hydrolase family GH169.

Authors:  Paeton L Wantuch; Satya Jella; Jeremy A Duke; Jarrod J Mousa; Bernard Henrissat; John Glushka; Fikri Y Avci
Journal:  Glycobiology       Date:  2021-04-01       Impact factor: 4.313

7.  A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies.

Authors:  Ahmet Ozdilek; Jiachen Huang; Rachelle Babb; Amy V Paschall; Dustin R Middleton; Jeremy A Duke; Liise-Anne Pirofski; Jarrod J Mousa; Fikri Y Avci
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

Review 8.  Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.

Authors:  Arno Thibau; Alexander A Dichter; Diana J Vaca; Dirk Linke; Adrian Goldman; Volkhard A J Kempf
Journal:  Med Microbiol Immunol       Date:  2019-12-01       Impact factor: 3.402

9.  Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.

Authors:  Donald Hurley; Carl Griffin; Mariano Young; Daniel A Scott; Michael W Pride; Ingrid L Scully; John Ginis; Joseph Severs; Kathrin U Jansen; William C Gruber; Wendy Watson
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

10.  Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.

Authors:  Brandon Essink; Charu Sabharwal; Kevin Cannon; Robert Frenck; Himal Lal; Xia Xu; Vani Sundaraiyer; Yahong Peng; Lisa Moyer; Michael W Pride; Ingrid L Scully; Kathrin U Jansen; William C Gruber; Daniel A Scott; Wendy Watson
Journal:  Clin Infect Dis       Date:  2022-08-31       Impact factor: 20.999

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.